Evidence-based medicine in the treatment of hypertension

doi:10.3877/cma.j.issn.2095-3216.2014.06.002

Abstract

Abstract:

Hypertension greatly affects the health of human beings in the world. It interacts with chronic kidney disease (CKD) in many different ways. CKD patients have a high morbidity of hypertension whose control rate is low, with high risk of cardiovascular disease (CVD) and death. Many guidelines and studies have shown that rational treatment of hypertension can slow down the progression of kidney diseases,prevent the damage of organs, decrease the morbidity of clinical diseases, and decrease the mortality of CVD in CKD patients. At present, it is recommended to use renin-angiotensin system (RAS) inhibitors, calcium channel blockers (CCBs), or combined therapy to achieve optimal blood pressure. There is no clinical practice guideline for management of CKD hypertension in China because of the deficiency of intervention information. The evidence-based medicine of hypertension in Chinese CKD patients is urgently needed.

Key words: Hypertension, Chronic kidney disease, Cardiovascular disease, Evidence-based medicine

Zhaohui Ni, Qi Zhang. Evidence-based medicine in the treatment of hypertension[J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2014, 03(06): 289-293.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsbyjdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3216.2014.06.002

https://zhsbyjdzzz.cma-cmc.com.cn/EN/Y2014/V03/I06/289

References 41

1	Agarwal R,Nissenson AR,Batlle D,et al. Prevalence,treatment,and control of hypertension in chronic hemodialysis patients in the United States [J]. Am J Med, 2003, 115(4): 291-297.
2	Zheng Y,Cai GY,Chen XM,et al. Prevalence,awareness,treatment,and control of hypertension in the non-dialysis chronic kidney disease patients [J]. Chin Med J (Engl), 2013, 126(12): 2276-2280.
3	Wang J,Zhang L,Wang F,et al. Prevalence,awareness,treatment,and control of hypertension in china:results from a national survey[J]. Am J Hypertens, 2014, 27(11):1355-1361.
4	胡大一,刘力生,余金明,等. 中国门诊高血压患者治疗现状登记研究[J]. 中华心血管病杂志,2010,42(3): 230-238.
5	Campese VM,Mitra N,Sandee D,et al. Hypertension in renal parenchymal disease:why is it so resistant to treatment [J]? Kidney Int,2006,69(6): 967-973.
6	Kidney Disease Outcomes Quality Initiative (K/DOQI). K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease [J]. Am J Kidney Dis,2004,43(5 Suppl 1): S1-S290.
7	Port FK. Practice-based versus patient-level outcomes research in hemodialysis:the DOPPS (Dialysis Outcomes and Practice Patterns Study) experience [J]. Am J Kidney Dis,2014,64(6): 969-977.
8	Klag MJ,Whelton PK,Randall BL,et al. Blood pressure and endstage renal disease in men [J]. N Engl J Med,1996,334(1):13-18.
9	Tozawa M,Iseki K,Iseki C,et al. Blood pressure predicts risk of developing end-stage renal disease in men and women [ J].Hypertension,2003,41(6):1341-1345.
10	Hsu CY,Iribarren C,McCulloch CE,et al. Risk factors for end-stage renal disease: 25-year follow-up [J]. Arch Intern Med,2009,169(4):342-350.
11	Ruilope LM,Salvetti A,Jamerson K,et al. Renal function and intensive lowering of blood pressure in hypertensive participants of the hypertension optimal treatment (HOT) study[J]. J Am Soc Nephrol,2001,12(2):218-225.
12	Mancia G,Fagard R,Narkiewicz K,et al. 2013 ESH/ESC Practice Guidelines for the Management of Arterial Hypertension [J]. Blood Press,2014,23(1):3-16.
13	Bakris GL,Williams M,Dworkin L,et al. Preserving renal function in adults with hypertension and diabetes:a consensus approach [J].National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis,2000,36(3):646-661.
14	Zanchetti A. Evidence-based medicine in hypertension:what type of evidence [J]? J Hypertens,2005,23(6):1113-1120.
15	Berl T1,Hunsicker LG,Lewis JB,et al. Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial [J]. J Am Soc Nephrol,2005,16(7):2170-2179.
16	James PA,Oparil S,Carter BL,et al. 2014 evidence-based guideline for the management of high blood pressure in adults:report from the panel members appointed to the Eighth Joint National Committee(JNC 8) [J]. JAMA,2014,311(5):507-520.
17	Brenner BM,Cooper ME,de Zeeuw D,et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy [J]. N Engl J Med,2001,345(12):861-869.
18	Parving HH,Lehnert H,Bröchner-Mortensen J,et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes [J]. N Engl J Med,2001,345(12):870-878.
19	Lewis EJ,Hunsicker LG,Clarke WR,et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes [J]. N Engl J Med,2001,345(12):851-860.
20	Evans M,Bain SC,Hogan S,et al. Irbesartan delays progression of nephropathy as measured by estimated glomerular filtration rate post hoc analysis of the Irbesartan Diabetic Nephropathy Trial [J].Nephrol Dial Transplant,2012,27(6):2255-2263.
21	Mancia G,Brown M,Castaigne A,et al. Outcomes with nifedipine GITS or Co-amilozide in hypertensive diabetics and nondiabetics in Intervention as a Goal in Hypertension ( INSIGHT) [ J].Hypertension,2003, 41(3):431-436.
22	Ohishi M,Takagi T,Ito N,et al. Renal-protective effect of T-and Ltype calcium channel blockers in hypertensive patients: an Amlodipine-to-Benidipine Changeover(ABC) study [ J ].Hypertens Res,2007,30(9):797-806.
23	Dahlöf B,Sever PS,Poulter NR,et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required,in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA):a multicentre randomised controlled trial [J]. Lancet,2005,366(9489):895-906.
24	Hasebe N,Kikuchi K,NICE Combi Study Group. Controlled-release nifedipine and candesartan low-dose combination therapy in patients with essential hypertension: the NICE Combi ( Nifedipine and Candesartan Combination) Study[J]. J Hypertens,2005,23(2):445-453.
25	Bakris GL,Sarafidis PA,Weir MR,et al. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH):a prespecified secondary analysis of a randomised controlled trial [J]. Lancet,2010,375(9721):1173-1181.
26	Yamada H,Suga N,Maeda K,et al. Effects of combination therapy with angiotensin II type I receptor blockers and calcium channel blockers on renal function in hypertensive patients/a retrospective,“real-world” comparative study [J]. Arzneimittelforschung,2010,60(2):64-70.
27	Yilmaz MI,Carrero JJ,Martín-Ventura JL,et al. Combined therapy with renin-angiotensin system and calcium channel blockers in type 2 diabetic hypertensive patients with proteinuria:effects on soluble TWEAK,PTX3,and flow-mediated dilation [J]. Clin J Am Soc Nephrol,2010,5(7):1174-1181.
28	Heerspink HJ,Ninomiya T,Zoungas S,et al. Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomised controlled trials [J]. Lancet,2009,373(9668):1009-1015.
29	Brugts JJ,Ninomiya T,Boersma E,et al. The consistency of the treatment effect of an ACE-inhibitor based treatment regimen in patients with vascular disease or high risk of vascular disease: a combined analysis of individual data of ADVANCE,EUROPA,and PROGRESS trials[J]. Eur Heart J,2009,30(11):1385-1394.
30	Klingbeil AU,Schneider M,Martus P,et al. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension[J]. Am J Med,2003,115(1): 41-46.
31	Gaudio C,Ferri FM,Giovannini M,et al. Comparative effects of irbesartan versus amlodipine on left ventricular mass index in hypertensive patients with left ventricular hypertrophy [ J]. J Cardiovasc Pharmacol,2003,42(5): 622-628.
32	Malmqvist K,Kahan T,Edner M,et al. Regression of left ventricular hypertrophy in human hypertension with irbesartan [ J]. J Hypertens,2001,19(6):1167-1176.
33	Berl T,Hunsicker LG,Lewis JB,et al. Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy [J]. Ann Intern Med,2003,138(7): 542-549.
34	Healey JS, Baranchuk A, Crystal E, et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers:a meta-analysis [J]. J Am Coll Cardiol,2005,45(11):1832-1839.
35	Madrid AH,Bueno MG,Rebollo JM,et al. Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation:a prospective and randomized study [J]. Circulation,2002,106(3):331-336.
36	Verdecchia P,Reboldi G,Angeli F,et al. Angiotensin-converting enzyme inhibitors and calcium channel blockers for coronary heart disease and stroke prevention [J]. Hypertension,2005,46(2):386-392.
37	Ruilope LM,Kirwan BA,de Brouwer S,et al. Uric acid and other renal function parameters in patients with stable angina pectoris participating in the ACTION trial:impact of nifedipine GITS (gastrointestinal therapeutic system) and relation to outcome [J]. J Hypertens,2007,25(8):1711-1718.
38	Saito Y,Shirai K,Uchino J,et al. Effect of nifedipine administration on pulse wave velocity (PWV) of chronic hemodialysis patients--2-year trial [J]. Cardiovasc Drugs Ther,1990,Suppl 5:987-990.
39	Ke YN,Dong YG,Ma SP,et al. Improved blood pressure control with nifedipine GITS/valsartan combination versus high-dose valsartan monotherapy in mild-to-moderate hypertensive patients from Asia:results from the ADVISE study,a randomized trial [J]. Cardiovasc Ther,2012,30(6): 326-332.
40	Wald DS,Law M,Morris JK,et al. Combination therapy versus monotherapy in reducing blood pressure:meta-analysis on 11000 participants from 42 trials [J]. Am J Med,2009,122(3):290-300.
41	Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients [J]. N Engl J Med,2008,359(23): 2417-2428.

[1]	Yueying Hao, Yingxuan Mao, Yu Zhang, Jiaxu Wang, Linlin Han, Wenwen Kuang, Yao Meng, Xiuhua Yang. Ultrasound guided attenuation parameter for evaluating hepatic steatosis and predicting risk of cardiovascular disease [J]. Chinese Journal of Medical Ultrasound (Electronic Edition), 2024, 21(08): 770-777.
[2]	Wenjia Cao, Xuebing Liu, Anguo Luo, Shimin Zhong, Lan Deng, Yulin Wang, Zhaohuan Li. Evaluation of wall shear stress of the carotid artery by ultrasound vector flow imaging in patients with type 2 diabetes mellitus [J]. Chinese Journal of Medical Ultrasound (Electronic Edition), 2024, 21(07): 709-717.
[3]	Xiaoqing Tang, Ping He, You Yang, Xia Luo, Juying Zhang, Xin Yang, Jinhong Yu. Correlation of sound touch elastography combined with pulsed wave Doppler ultrasound imaging parameters with stage of early chronic kidney disease and their clinical significance [J]. Chinese Journal of Medical Ultrasound (Electronic Edition), 2024, 21(05): 491-499.
[4]	Xiaoling Chen, Yonglie Zhong, Qiaoli Liu, Na Li, Zhiqi Zhang, Weiming Liao, Guiwu Huang. Risk prediction of delirium and cardiovascular complications after hip and knee surgeries in elderly patients [J]. Chinese Journal of Joint Surgery(Electronic Edition), 2024, 18(05): 575-584.
[5]	Yigang Wu, Yumin Pan, Shanshan Wu, Mengjuan Hu, Yiwei Wang, Jinsong Zhang, Li Qiao. Efficacy of levosimendan in the treatment of pulmonary hypertension combined with right heart failure: a meta-analysis [J]. Chinese Journal of Critical Care Medicine(Electronic Edition), 2024, 17(05): 385-391.
[6]	Jingyu Qian, Mingming Zheng. Interpretation of the Italian guidelines on non-invasive and invasive prenatal diagnosis：executive summary of recommendations for practice the Italian Society for Obstetrics and Gynecology（SIGO） [J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2024, 20(05): 486-492.
[7]	Zhipeng Jiang, Keli Zhong, Shuang Chen. Prevention and management of abdominal hypertension and abdominal compartment syndrome after complex abdominal wall hernia surgery [J]. Chinese Journal of Hernia and Abdominal Wall Surgery(Electronic Edition), 2024, 18(06): 612-615.
[8]	Yidan Cai, Fang Jian, Zhiqiang Zhang, Li Chen, Shian Zhang, Lei Xia, Mei Ruan, Dongliang Li. Impact of transjugular intrahepatic portosystemic shunt on gut microbiota and liver function in patients with cirrhotic portal hypertension [J]. Chinese Journal of Cell and Stem Cell(Electronic Edition), 2024, 14(05): 285-293.
[9]	Bokai Cheng, Guang Yang. Progress of research on application of hyperinsulinemic-euglycemic clamp technique for assessing insulin resistance in patients with chronic kidney disease [J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2024, 13(06): 334-339.
[10]	Rongrong Feng, Xiaole Su, Lihua Wang. Research progress on biological markers related to complication of cardiovascular disease in patients with chronic kidney disease [J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2024, 13(05): 273-278.
[11]	Junnan Guo, Hui Lin, Yilin Ren, Xi Qiao. Progress of research on the role of amino acid metabolism disturbance in the transition from AKI to CKD [J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2024, 13(05): 283-287.
[12]	Minwei Zhang, Tianxu Zhai, Ziqiu Zhang, Chi Wang, Shengzhong Liu, Dechun Li. Development of a predictive nomogram model integrating abdominal CT imaging and clinical parameters for assessing the risk of elevated intra-abdominal pressure [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2024, 14(06): 549-554.
[13]	Yanping Liang, Yanrou Chen, Yunxiao Liang, Feihu Bai, Bin Wu, Xing Wang. Investigation report on endoscopic management of esophagogastric variceal bleeding in portal hypertension in Southern China [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2024, 14(05): 390-395.
[14]	Lingling Jia, Fei Teng, Jian Chang, Fu Huang, Jianping Liu. Progress in application of cardiopulmonary rehabilitation in various diseases [J]. Chinese Journal of Clinicians(Electronic Edition), 2024, 18(09): 859-862.
[15]	Peipei Xi, Jiajun Zhou. Progress in research of sarcopenia in patients with chronic kidney disease: pathogenesis, diagnosis, and treatment [J]. Chinese Journal of Clinicians(Electronic Edition), 2024, 18(05): 491-495.

Please choose a citation manager

Content to export